Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma

Gynecologic Oncology

Volumn 131, Issue 1, 2013, Pages 63-68

  Chen, Yu Li ^a,b   Cheng, Wen Fang ^a   Chang, Ming Cheng ^a   Lin, Han Wei ^a   Huang, Ching Ting ^a   Chien, Chung Liang ^a   Chen, Chi An ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Ascites; Cytokine; Interferon gamma; Ovarian carcinoma; Tumor immunology

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASCITES; ASCITES FLUID ANALYSIS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; ENDOMETRIOID ADENOCARCINOMA.; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MUCINOUS ADENOCARCINOMA; OUTCOME ASSESSMENT; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; SEROUS ADENOCARCINOMA; TUMOR MICROENVIRONMENT;

EID: 84885295979     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.07.105     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69-90.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003;3: 502-16.
3. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003;90:S24-32.
4. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351: 2519-29.
5. Rustin GJ. Tumour markers for ovarian cancer. Eur J Cancer 1992;28: 2-3.
6. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12: 337-65.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10: 942-9.
8. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intra-tumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348: 203-13.
9. Tomsová M, Melichar B, Sedláková I, Steiner I. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008;108: 415-20.
10. Raspollini MR, Castiglione F, Rossi Degl'innocenti D. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol 2005;16: 590-6.
11. Giuntoli II RL,Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009;29: 2875-84.
12. Chen YL, Chang MC, Chen CA, Lin HW, ChengWF, Chien CL. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PLoS One 2012;7:e47190.
13. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 1971;50: 1-7.
14. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1987;156: 263-4.
15. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007;13: 2385-91.
16. Wakelkamp IM, Gerding MN, Van Der Meer JW, Prummel MF,Wiersinga WM. Both Th1 and Th2-derived cytokines in serum are elevated in Graves' ophthalmopathy. Clin Exp Immunol 2000;121: 453-7.
17. Chen YL, Chang MC, Huang CY, Chiang YC, Lin HW, Chen CA, et al. Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response. Mol Oncol 2012;6: 360-9.
18. Baune BT, RothermundtM, Ladwig KH,Meisinger C, Berger K. Systemic inflammation (Interleukin 6) predicts all-cause mortality in men: results from a 9-year follow-up of the MEMO Study. Age 2011;33: 209-17.
19. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13: 251-76.
20. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010;238: 247-62.
21. Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R,Massuger LF. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 2011;47: 1883-9.
22. Lane D, Matte I, Rancourt C, Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011;11:210.
23. Cândido EB, Silva LM, Carvalho AT, Lamaita RM, Filho RM, Cota BD, et al. Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reprod Sci 2013;20: 828-37.
24. Rawlings JO. Collinearity diagnostics. In: Barndorff-Nielsen OE, Bickel PJ, Cleveland WS, Dudley RM, editors. Applied Regression Analysis. Pacific Grove: Wadsworth and Brooks; 1988. p. 273-81.
25. Shankaran V, Ikeda H, Bruce AT,White JM, Swanson PE, Old LJ. IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410: 1107-11.
26. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immuno-editing: from immuno-surveillance to tumor escape. Nat Immunol 2002;3: 991-8.
27. Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, Jager MJ, et al. Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J Immunol 2008;180: 3766-74.
28. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002;13: 95-109.
29. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1: 447-56.
30. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95: 7556-61.
31. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196: 129-34.
32. Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn Jr JM. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 2009;114: 242-5.
33. Miller CH, Maher SG, Young HA. Clinical use of interferon-gamma. Ann N Y Acad Sci 2009;1182: 69-79.
34. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, et al. Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study. Int J Gynecol Cancer 2006;16: 1522-8.
35. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, François E, Fumoleau P, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14: 343-50.
36. Windbichler GH, Hausmaninger H, StummvollW, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82: 1138-44.
37. Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008;109: 174-81.
38. Malkasian Jr GD, Melton III LJ, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelialmalignancies of the ovary. AmJ Obstet Gynecol 1984;149: 274-84.
39. Swenerton KD,Hislop TG, Spinelli J, LeRiche JC, Yang N, BoyesDA.Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65: 264-70.